Related Experiment Videos
The case for mitomycin in non-small cell lung cancer
1Division of Oncology, St. Luke's Hospital, Cleveland, OH 44104.
Abstract:
The activity of mitomycin in non-small cell lung cancer (NSCLC) has been well documented in both single-institution pilot and multi-institution randomized trials. Despite the inclusion of patients ineligible for current trials of newer single agents due to poor performance status, prior irradiation to indicator lesions, or prior chemotherapy, mitomycin emerges from such prior studies as the most consistently active single agent currently available for NSCLC. While randomized trials in stage IV disease demonstrate an improved response rate with mitomycin and cisplatin in comparison with cisplatin alone (p = 0.03), and with mitomycin, vindesine, and cisplatin in comparison with vindesine and cisplatin alone (p = 0.003), the potential with mitomycin is most apparent with weekly bolus or infused vindesine/vinblastine, and higher-dose cisplatin (MVP) in neoadjuvant approaches to stage III disease. Indeed, four trials of neoadjuvant MVP in predominantly stage IIIA (bulky N2) disease produced a consistent 19-month median and 26-33% 3-year survival, which is to be compared with 8 months and 6%, respectively, with traditional thoracic irradiation alone. Nonetheless, prior use of mitomycin without guidelines for cumulative dose, schedule, or guidelines for use in combined-modality therapy has produced widespread frustration stemming not only from frequent antineoplastic effect, but also from frequent toxicity. The several related syndromes of mitomycin-associated thrombotic microangiopathy, ranging from hemolytic-uremic syndrome to pulmonary injury, appear avoidable through limiting the cumulative mitomycin dose to a maximum of 30 mg/m2; scheduling mitomycin at not less than 4- to 6-week intervals; perioperative use of corticosteroids and low inspired oxygen; and close patient follow-up. While dexamethasone preceding mitomycin reduces the frequency and severity of mitomycin-associated lung injury (p = 0.0005), dexamethasone premedication also reduces the response rate of MVP in NSCLC (p < 0.025).
Insights
Mitomycin demonstrates consistent activity in non-small cell lung cancer (NSCLC), particularly in neoadjuvant settings for stage III disease. Careful dosing and scheduling can mitigate toxicity, improving patient outcomes.
Area of Science:
- Oncology
- Medical Oncology
- Thoracic Oncology
Background:
- Mitomycin has shown consistent single-agent activity in non-small cell lung cancer (NSCLC).
- Its efficacy is noted even in patients with poor performance status or prior treatments, often excluded from other trials.
- Previous studies highlight its potential in combination therapies, especially for advanced NSCLC stages.
Purpose of the Study:
- To review the documented activity of mitomycin in non-small cell lung cancer (NSCLC).
- To evaluate the efficacy of mitomycin-based regimens, particularly the Mitomycin, Vindesine, and Cisplatin (MVP) regimen, in neoadjuvant settings for stage III NSCLC.
- To identify strategies for managing mitomycin-associated toxicities.
Main Methods:
- Review of single-institution pilot studies and multi-institution randomized trials involving mitomycin in NSCLC.
- Analysis of treatment outcomes from trials using mitomycin in combination with other chemotherapeutic agents (e.g., cisplatin, vindesine/vinblastine).
- Examination of data related to mitomycin-associated toxicities and proposed management guidelines.
Main Results:
- Randomized trials show improved response rates with mitomycin and cisplatin versus cisplatin alone (p = 0.03).
- Neoadjuvant MVP regimens in stage III NSCLC achieved a median survival of 19 months and 3-year survival of 26-33%, significantly better than thoracic irradiation alone.
- Mitomycin-associated toxicities, including thrombotic microangiopathy and pulmonary injury, can be reduced by limiting cumulative dose to 30 mg/m², maintaining 4-6 week intervals, and using perioperative corticosteroids.
Conclusions:
- Mitomycin is a valuable agent in NSCLC treatment, especially in neoadjuvant MVP regimens for stage III disease.
- Strict adherence to cumulative dose limits and appropriate scheduling can minimize severe toxicities.
- While dexamethasone can reduce lung injury, it may also decrease the response rate of MVP regimens in NSCLC.